Next-generation medicine: combining BCR-ABL and Hedgehog-targeted therapies.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23382113.
- Also identified by DOI 10.1158/1078-0432.CCR-12-3934 and PMC identifier 3602391.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.
Medical subject headings
- Anilides
- Antineoplastic Combined Chemotherapy Protocols
- Drug Resistance, Neoplasm
- Imidazoles
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Pyridazines
- Pyridines